10.1647/1082-6742-34.4.348 41 IlyasU.KatareD
Chen Y, Deng J, Fujimoto J, Kadara H, Men T, Lotan D, et al
Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists Source In both trials, after 72 weeks of treatment, patients who received Zepbound at all three dose levels experienced a statistically significant reduction in body weight compared to those who received placebo, and greater proportions of patients who received Zepbound achieved at least 5% weight reduction compared to placebo
$5.43 $7.75 Paba 100 mg $5.43 Paba 100 mg On Sale
It does not provide exogenous GLP-1
The primary concerns include cholelithiasis (gallstones), cholecystitis (gallbladder inflammation), and choledocholithiasis (bile duct stones)